Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
Pancreatic adenocarcinoma has a 5-year overall survival rate of 9 %, with an outlook of becoming the second leading cause of cancer mortality in the USA by 2030. Familial pancreatic cancer and genetic predisposition syndromes have attracted more interest in the perspective of targeted therapy. Vari...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Bashkir State Medical University
2022-06-01
|
| Sarja: | Креативная хирургия и онкология |
| Aiheet: | |
| Linkit: | https://www.surgonco.ru/jour/article/view/674 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|